# Study of Pemetrexed for Second-Line Pancreas Cancer

> **NCT00864513** · PHASE2 · TERMINATED · sponsor: **Georgetown University** · enrollment: 17 (actual)

## Conditions studied

- Pancreas Cancer

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00864513
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** At interim analysis the study did not meet the response criteria to continue
- **Last updated:** 2015-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864513, "Study of Pemetrexed for Second-Line Pancreas Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00864513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*